DC Field | Value | Language |
---|---|---|
dc.contributor.author | IM, SIN HYEOG | - |
dc.date.accessioned | 2022-12-05T08:40:10Z | - |
dc.date.available | 2022-12-05T08:40:10Z | - |
dc.date.created | 2022-12-01 | - |
dc.date.issued | 2022-12 | - |
dc.identifier.issn | 2001-3078 | - |
dc.identifier.uri | https://oasis.postech.ac.kr/handle/2014.oak/114519 | - |
dc.description.abstract | T cell-derived small extracellular vesicles (sEVs) exhibit anti-cancer effects. However, their anti-cancer potential should be reinforced to enhance clinical applicability. Herein, we generated interleukin-2-tethered sEVs (IL2-sEVs) from engineered Jurkat T cells expressing IL2 at the plasma membrane via a flexible linker to induce an autocrine effect. IL2-sEVs increased the anti-cancer ability of CD8+ T cells without affecting regulatory T (Treg ) cells and down-regulated cellular and exosomal PD-L1 expression in melanoma cells, causing their increased sensitivity to CD8+ T cell-mediated cytotoxicity. Its effect on CD8+ T and melanoma cells was mediated by several IL2-sEV-resident microRNAs (miRNAs), whose expressions were upregulated by the autocrine effects of IL2. Among the miRNAs, miR-181a-3p and miR-223-3p notably reduced the PD-L1 protein levels in melanoma cells. Interestingly, miR-181a-3p increased the activity of CD8+ T cells while suppressing Treg cell activity. IL2-sEVs inhibited tumour progression in melanoma-bearing immunocompetent mice, but not in immunodeficient mice. The combination of IL2-sEVs and existing anti-cancer drugs significantly improved anti-cancer efficacy by decreasing PD-L1 expression in vivo. Thus, IL2-sEVs are potential cancer immunotherapeutic agents that regulate both immune and cancer cells by reprogramming miRNA levels. | - |
dc.language | English | - |
dc.publisher | Co-Action Publishing | - |
dc.relation.isPartOf | Journal of Extracellular Vesicles | - |
dc.title | Reprogramming of T cell-derived small extracellular vesicles using IL2 surface engineering induces potent anti-cancer effects through miRNA delivery | - |
dc.type | Article | - |
dc.identifier.doi | 10.1002/jev2.12287 | - |
dc.type.rims | ART | - |
dc.identifier.bibliographicCitation | Journal of Extracellular Vesicles, v.11, no.12, pp.e12287 | - |
dc.identifier.wosid | 000892038100001 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | e12287 | - |
dc.citation.title | Journal of Extracellular Vesicles | - |
dc.citation.volume | 11 | - |
dc.contributor.affiliatedAuthor | IM, SIN HYEOG | - |
dc.identifier.scopusid | 2-s2.0-85143054325 | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | EXOSOMES | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | INTERLEUKIN-2 | - |
dc.subject.keywordPlus | DACARBAZINE | - |
dc.subject.keywordPlus | BIOGENESIS | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | RECEPTORS | - |
dc.subject.keywordPlus | IMMUNITY | - |
dc.subject.keywordPlus | GROWTH | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | exosomal PD-L1 | - |
dc.subject.keywordAuthor | interleukin-2 | - |
dc.subject.keywordAuthor | PD-L1 | - |
dc.subject.keywordAuthor | small extracellular vesicle | - |
dc.subject.keywordAuthor | small extracellular vesicle engineering | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
library@postech.ac.kr Tel: 054-279-2548
Copyrights © by 2017 Pohang University of Science ad Technology All right reserved.